HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast cancer is distinct in its response to hormone therapies due to the presence ...

Whether you have HER2-positive breast cancer, HER2-negative, or something else entirely, the type of cancer you have will determine your treatment & prognosis.

That said, generally speaking, survival rates are 90% or higher for most with HER2-positive breast cancer that's caught early and treated with chemotherapy and an additional antibody therapy ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

Access free, up-to-date clinical references about the natural history and prognosis of HER2-positive breast cancer. Healio's Clinical Guidance content provides valuable insights for physicians.

Despite the rapid advances being made when it comes to the treatment of patients with HER2-positive metastatic breast cancer, which have led to an improved outlook for survival rates, patients ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

First-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) plus Perjeta (pertuzumab) demonstrated highly statistically significant and clinically meaningful improvement in progression-free ...

HER2-Low Expression and Prognosis for HR-Positive Early Breast Cancer —A first-of-its-kind study from Israel suggests better outcomes for patients at high genomic risk with HER2-low, versus HER2 ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with HER2-positive breast cancer, according to long-term results of a randomized ...

Generally, HER2-negative breast cancers tend to be less aggressive and have a better prognosis than HER2-positive breast cancers. However, your outlook can vary, depending on a variety of factors. [4] ...

Overall survival in metastatic HER2-positive breast cancer varied by location of brain lesions. Patients with central nervous system (CNS)-only disease had a higher risk of CNS-related death ...